Primary endpoint
Objective response rate.
phase 2 · Active, not recruiting
Phase 2 single-arm study of BPC-402 in EGFR-mutant NSCLC
Single-arm Phase 2 evaluating BPC-402 at the recommended Phase 2 dose in patients with EGFR-mutant NSCLC after at least two prior regimens.
Investigational candidate. BPC-402 has not been approved by any regulatory authority.
Enrollment
Patient participation.
Enrolled 220
Target 220
Sites 6
100% of target enrollment reached.
Design
Trial endpoints.
Secondary endpoints
- Duration of response
- Progression-free survival
- Safety
Eligibility
Adults with EGFR-mutant NSCLC after platinum-based chemotherapy and an EGFR TKI.
Timeline
- Started
- February 1, 2024
Sites
6 sites for NCT-BPC402-201.
- Cambridge, United States
Cambridge Research Center
245 Binney Street, Cambridge, MA 02142
- Boston, United States
Mass General Cancer Center
55 Fruit Street, Boston, MA 02114
- Houston, United States
Texas Cancer Institute
1515 Holcombe Boulevard, Houston, TX 77030
- Los Angeles, United States
West Coast Cancer Center
200 UCLA Medical Plaza, Los Angeles, CA 90095
- Tokyo, Japan
National Tokyo Medical Center
2-1-21 Higashigaoka, Meguro-ku, Tokyo 152-0021
- London, United Kingdom
London Cancer Institute
250 Euston Road, London NW1 2PG